Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Victoria E. Walker-Sperling is active.

Publication


Featured researches published by Victoria E. Walker-Sperling.


The Journal of Infectious Diseases | 2015

A Murine Viral Outgrowth Assay to Detect Residual HIV Type 1 in Patients With Undetectable Viral Loads

Kelly A. Metcalf Pate; Christopher W. Pohlmeyer; Victoria E. Walker-Sperling; Jeremy B. Foote; Kevin M. Najarro; Catherine G. Cryer; Maria Salgado; Lucio Gama; Elizabeth L. Engle; Erin N. Shirk; Suzanne E. Queen; Stanley Chioma; Meghan S. Vermillion; Brandon T. Bullock; Ming Li; Claire E. Lyons; Robert J. Adams; M. Christine Zink; Janice E. Clements; Joseph L. Mankowski; Joel N. Blankson

BACKGROUND Sensitive assays are needed for detection of residual human immunodeficiency virus (HIV) in patients with undetectable plasma viral loads to determine whether eradication strategies are effective. The gold standard quantitative viral outgrowth assay (QVOA) underestimates the magnitude of the viral reservoir. We sought to determine whether xenograft of leukocytes from HIV type 1 (HIV)-infected patients with undetectable plasma viral loads into immunocompromised mice would result in viral amplification. METHODS Peripheral blood mononuclear cells or purified CD4(+) T cells from HIV or simian immunodeficiency virus (SIV)-infected subjects with undetectable plasma viral loads were adoptively transferred into NOD.Cg-Prkdc(scid)Il2rg(tm1Wjl)/SzJ (NSG) mice. The mice were monitored for viremia following depletion of human CD8(+) T cells to minimize antiviral activity. In some cases, humanized mice were also treated with activating anti-CD3 antibody. RESULTS With this murine viral outgrowth assay (MVOA), we successfully amplified replication-competent HIV or SIV from all subjects tested, including 5 HIV-positive patients receiving suppressive antiretroviral therapy (ART) and 6 elite controllers or suppressors who were maintaining undetectable viral loads without ART, including an elite suppressor from whom we were unable to recover virus by QVOA. CONCLUSIONS Our results suggest that the MVOA has the potential to serve as a powerful tool to identify residual HIV in patients with undetectable viral loads.


EBioMedicine | 2016

The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication

Victoria E. Walker-Sperling; Christopher W. Pohlmeyer; Patrick M. Tarwater; Joel N. Blankson

Shock and kill strategies involving the use of small molecules to induce viral transcription in resting CD4 + T cells (shock) followed by immune mediated clearance of the reactivated cells (kill), have been proposed as a method of eliminating latently infected CD4 + T cells. The combination of the histone deacetylase (HDAC) inhibitor romidepsin and protein kinase C (PKC) agonist bryostatin-1 is very effective at reversing latency in vitro. However, we found that primary HIV-1 specific CD8 + T cells were not able to eliminate autologous resting CD4 + T cells that had been reactivated with these drugs. We tested the hypothesis that the drugs affected primary CD8 + T cell function and found that both agents had inhibitory effects on the suppressive capacity of HIV-specific CD8 + T cells from patients who control viral replication without antiretroviral therapy (elite suppressors/controllers). The inhibitory effect was additive and multi-factorial in nature. These inhibitory effects were not seen with prostratin, another PKC agonist, either alone or in combination with JQ1, a bromodomain-containing protein 4 inhibitor. Our results suggest that because of their adverse effects on primary CD8 + T cells, some LRAs may cause immune-suppression and therefore should be used with caution in shock and kill strategies.


Journal of Virology | 2014

Comparative Analysis of the Capacity of Elite Suppressor CD4+ and CD8+ T Cells To Inhibit HIV-1 Replication in Monocyte-Derived Macrophages

Victoria E. Walker-Sperling; Robert W. Buckheit; Joel N. Blankson

ABSTRACT Elite controllers or suppressors (ESs) are HIV-1-infected individuals who are able to maintain viral loads below the limit of detection of clinical assays without antiretroviral therapy. The mechanisms of virologic control are not fully understood, but ESs have been shown to have a more effective CD8+ T cell response to infected CD4+ T cells than chronic progressors (CPs). While macrophages are another cell type productively infected by HIV-1, few studies have examined the ability of primary effector T cells to suppress HIV-1 replication in these target cells. Here, we compared the ability of unstimulated primary CD4+ and CD8+ effector T cells to suppress viral replication in monocyte-derived macrophages (MDMs) in ESs and CPs. While CD4+ effector T cells were capable of inhibiting viral replication in MDMs, the magnitude of this response was not significantly different between ESs and CPs. In contrast, the CD8+ T cells from ESs were significantly more effective than those from CPs at inhibiting viral replication in MDMs. The CD4+ T cell response was partially mediated by soluble factors, while the CD8+ T cell response required cell-to-cell interaction. Our results suggest that the individual contributions of various effector cells should be considered in rational vaccine design and in ongoing eradication efforts. IMPORTANCE Elite suppressors are individuals capable of maintaining low-level viremia in HIV-1 infection without antiretroviral drugs. Their T cell responses have been implicated in eliminating infected CD4+ T cells, and as such, elite suppressors may represent a model of a functional cure of HIV-1 infection. Here, we sought to determine whether the suppressive T cell responses against infected CD4+ T cells also apply to infected macrophages by comparing the responses of elite suppressors and HIV-1-positive individuals on highly active antiretroviral therapy (HAART). Our results show that the CD8+ cells but not CD4+ T cells from elite suppressors have a response against infected macrophages superior to the response of CD8+ cells from patients on HAART. Our results suggest that the induction of a CD8+ T cell response effective against infected macrophages is an outcome to consider in rational vaccine design.


Journal of Virology | 2015

Reactivation kinetics of HIV-1 and susceptibility of reactivated latently infected CD4+ T cells to HIV-1-specific CD8+ T cells

Victoria E. Walker-Sperling; Valerie J. Cohen; Patrick M. Tarwater; Joel N. Blankson

ABSTRACT The “shock and kill” model of human immunodeficiency virus type 1 (HIV-1) eradication involves the induction of transcription of HIV-1 genes in latently infected CD4+ T cells, followed by the elimination of these infected CD4+ T cells by CD8+ T cells or other effector cells. CD8+ T cells may also be needed to control the spread of new infection if residual infected cells are present at the time combination antiretroviral therapy (cART) is discontinued. In order to determine the time frame needed for CD8+ T cells to effectively prevent the spread of HIV-1 infection, we examined the kinetics of HIV transcription and virus release in latently infected cells reactivated ex vivo. Isolated resting, primary CD4+ T cells from HIV-positive (HIV+) subjects on suppressive regimens were found to upregulate cell-associated HIV-1 mRNA within 1 h of stimulation and produce extracellular virus as early as 6 h poststimulation. In spite of the rapid kinetics of virus production, we show that CD8+ T cells from 2 out of 4 viremic controllers were capable of effectively eliminating reactivated autologous CD4+ cells that upregulate cell-associated HIV-1 mRNA. The results have implications for devising strategies to prevent rebound viremia due to reactivation of rare latently infected cells that persist after potentially curative therapy. IMPORTANCE A prominent HIV-1 cure strategy termed “shock and kill” involves the induction of HIV-1 transcription in latently infected CD4+ T cells with the goal of elimination of these cells by either the cytotoxic T lymphocyte response or other immune cell subsets. However, the cytotoxic T cell response may also be required after curative treatment if residual latently infected cells remain. The kinetics of HIV-1 reactivation indicate rapid upregulation of cell-associated HIV-1 mRNA and a 5-h window between transcription and virus release. Thus, HIV-specific CD8+ T cell responses likely have a very short time frame to eliminate residual latently infected CD4+ T cells that become reactivated after discontinuation of antiretroviral therapy following potentially curative treatment strategies.


EBioMedicine | 2017

Factors Associated With the Control of Viral Replication and Virologic Breakthrough in a Recently Infected HIV-1 Controller

Victoria E. Walker-Sperling; Christopher W. Pohlmeyer; Rebecca T. Veenhuis; Megan May; Krystle Luna; Allison R. Kirkpatrick; Oliver Laeyendecker; Andrea L. Cox; Mary Carrington; Justin R. Bailey; Roberto C. Arduino; Joel N. Blankson

HIV-1 controllers are patients who control HIV-1 viral replication without antiretroviral therapy. Control is achieved very early in the course of infection, but the mechanisms through which viral replication is restricted are not fully understood. We describe a patient who presented with acute HIV-1 infection and was found to have an HIV-1 RNA level of < 100 copies/mL. She did not have any known protective HLA alleles, but significant immune activation of CD8 + T cells and natural killer (NK) cells was present, and both cell types inhibited viral replication. Virus cultured from this patient replicated as well in vitro as virus isolated from her partner, a patient with AIDS who was the source of transmission. Virologic breakthrough occurred 9 months after her initial presentation and was associated with an increase in CD4 + T cell activation levels and a significant decrease in NK cell inhibitory capacity. Remarkably, CD8 + T cell inhibitory capacity was preserved and there were no new escape mutations in targeted Gag epitopes. These findings suggest that fully replication-competent virus can be controlled in acute HIV-1 infection in some patients without protective HLA alleles and that NK cell responses may contribute to this early control of viral replication.


PLOS Genetics | 2018

Identification of an elaborate NK-specific system regulating HLA-C expression

Hongchuan Li; Martin A. Ivarsson; Victoria E. Walker-Sperling; Jeff Subleski; Jenna K. Johnson; Paul W. Wright; Mary Carrington; Niklas K. Björkström; Daniel W. McVicar; Stephen K. Anderson

The HLA-C gene appears to have evolved in higher primates to serve as a dominant source of ligands for the KIR2D family of inhibitory MHC class I receptors. The expression of NK cell-intrinsic MHC class I has been shown to regulate the murine Ly49 family of MHC class I receptors due to the interaction of these receptors with NK cell MHC in cis. However, cis interactions have not been demonstrated for the human KIR and HLA proteins. We report the discovery of an elaborate NK cell-specific system regulating HLA-C expression, indicating an important role for HLA-C in the development and function of NK cells. A large array of alternative transcripts with differences in intron/exon content are generated from an upstream NK-specific HLA-C promoter, and exon content varies between HLA-C alleles due to SNPs in splice donor/acceptor sites. Skipping of the first coding exon of HLA-C generates a subset of untranslatable mRNAs, and the proportion of untranslatable HLA-C mRNA decreases as NK cells mature, correlating with increased protein expression by mature NK cells. Polymorphism in a key Ets-binding site of the NK promoter has generated HLA-C alleles that lack significant promoter activity, resulting in reduced HLA-C expression and increased functional activity. The NK-intrinsic regulation of HLA-C thus represents a novel mechanism controlling the lytic activity of NK cells during development.


AIDS Research and Human Retroviruses | 2016

HIV Controller T Cells Effectively Inhibit Viral Replication in Alveolar Macrophages

Victoria E. Walker-Sperling; Christian A. Merlo; Robert W. Buckheit; Allison A. Lambert; Patrick M. Tarwater; Gregory D. Kirk; Brad Drummond; Joel N. Blankson

Macrophages are targets of HIV-1 infection, and control of viral replication within these cells may be an important component of a T-cell-based vaccine. Although several studies have analyzed the ability of CD8+ T cells to inhibit viral replication in monocyte-derived macrophages, the effect of T cells on HIV-1-infected tissue macrophages is less clear. We demonstrate here that both CD4+ and CD8+ T-cell effectors from HIV controllers are capable of suppressing viral replication in bronchoalveolar lavage-derived alveolar macrophages. These findings have implications for HIV-1 vaccine and eradication strategies.


Open Forum Infectious Diseases | 2015

A Human Immunodeficiency Virus Controller With a Large Population of CD4+CD8+ Double-Positive T Cells

Christine M. Durand; Robert W. Buckheit; Maria Salgado; Christopher W. Pohlmeyer; Victoria E. Walker-Sperling; Robert W. Hegarty; Richard F. Ambinder; Joel N. Blankson

Human immunodeficiency virus (HIV) controllers are patients who control viral replication without antiretroviral therapy. We present the case of an HIV controller who had CD4 and CD8 coexpressed on 40% of his T cells. Although a recent study found that double-positive T cells had superior antiviral capacity in HIV-1 controllers, in this case, the CD4+CD8+ T cells did not have strong antiviral activity.


Human Immunology | 2018

P069UTR SNPS rs111686073 and rs73410010 independently modify expression of tapasin in blacks

Victoria E. Walker-Sperling; Veron Ramsuran; Maureen P. Martin; Vivek Naranbhai; Hongchuan Li; Stephen K. Anderson; Sarah Rowland-Jones; L.-M. Yindom; Musie Ghebremichael; Thumbi Ndung’u; Bruce D. Walker; Mary Carrington


Archive | 2015

A Human Immunodeficiency Virus Controller With a Large Population

Christine M. Durand; Robert W. Buckheit; Maria Salgado; Christopher W. Pohlmeyer; Victoria E. Walker-Sperling; Robert W. Hegarty; Richard F. Ambinder; Joel N. Blankson

Collaboration


Dive into the Victoria E. Walker-Sperling's collaboration.

Top Co-Authors

Avatar

Joel N. Blankson

Johns Hopkins University School of Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Robert W. Buckheit

Johns Hopkins University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Maria Salgado

Johns Hopkins University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Patrick M. Tarwater

Texas Tech University Health Sciences Center

View shared research outputs
Top Co-Authors

Avatar

Christine M. Durand

Johns Hopkins University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Hongchuan Li

Science Applications International Corporation

View shared research outputs
Top Co-Authors

Avatar

Robert W. Hegarty

Johns Hopkins University School of Medicine

View shared research outputs
Researchain Logo
Decentralizing Knowledge